SLYND Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Slynd, and when can generic versions of Slynd launch?
Slynd is a drug marketed by Exeltis Usa Inc and is included in one NDA. There are fourteen patents protecting this drug and one Paragraph IV challenge.
This drug has sixty-five patent family members in twenty-nine countries.
The generic ingredient in SLYND is drospirenone. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the drospirenone profile page.
DrugPatentWatch® Generic Entry Outlook for Slynd
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be June 28, 2031. This may change due to patent challenges or generic licensing.
There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
There is one tentative approval for the generic drug (drospirenone), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
AI Research Assistant
Sample questions
- What is the 5 year forecast for SLYND?
- What are the global sales for SLYND?
- What is Average Wholesale Price for SLYND?
Summary for SLYND
| International Patents: | 65 |
| US Patents: | 14 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 79 |
| Patent Applications: | 2,065 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for SLYND |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SLYND |
| What excipients (inactive ingredients) are in SLYND? | SLYND excipients list |
| DailyMed Link: | SLYND at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SLYND
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Paragraph IV (Patent) Challenges for SLYND
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| SLYND | Tablets | drospirenone | 4 mg | 211367 | 1 | 2022-01-07 |
US Patents and Regulatory Information for SLYND
SLYND is protected by fourteen US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of SLYND is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting SLYND
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SLYND
When does loss-of-exclusivity occur for SLYND?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 1670
Patent: COMPOSICION FARMACEUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 11273605
Patent: Pharmaceutical composition comprising drospirenone and contraceptive kit
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2012033391
Patent: kit contraceptivo, método contraceptivo para uma paciente do sexo feminino necessitando do mesmo e composição farmacêutica compreendendo drospirenova.
Estimated Expiration: ⤷ Sign Up
Patent: 2019008317
Patent: kit contraceptivo, método contraceptivo para uma paciente do sexo feminino necessitando do mesmo e composição farmacêutica compreendendo drospirenona
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 03721
Patent: COMPOSITION PHARMACEUTIQUE CONTENANT DE LA DROSPIRENONE ET KIT CONTRACEPTIF (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT)
Estimated Expiration: ⤷ Sign Up
Patent: 03062
Patent: COMPOSITION PHARMACEUTIQUE CONTENANT DE LA DROSPIRENONE ET KIT CONTRACEPTIF (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT)
Estimated Expiration: ⤷ Sign Up
Patent: 61421
Patent: METHOD OF PROVIDING CONTRACEPTION IN A PATIENT
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 12003685
Patent: Kit farmaceutico que comprende una o mas unidades de envasado que comprenden 21 a 28 unidades de dosificacion activas diarias en que cada una comprende por lo menos 2 mg de drosperidona, sin estrogernos; uso del kit y de una composicion farmaceutica que comprende drosperidona para preparar un medicamento util como anticonceptivo.
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 40328
Patent: Composición farmacéutica que comprende drospirenona y kit anticonceptivo
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0200155
Estimated Expiration: ⤷ Sign Up
Patent: 0220332
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 22544
Estimated Expiration: ⤷ Sign Up
Patent: 25061
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 88114
Estimated Expiration: ⤷ Sign Up
Patent: 32448
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 12012359
Patent: COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO
Estimated Expiration: ⤷ Sign Up
Patent: 15032906
Patent: COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO (DIVISIONAL 2 DE SOLICITUD No. SP-12-12359 PCT)
Estimated Expiration: ⤷ Sign Up
Patent: 15032911
Patent: COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO (DIVISIONAL 1 DE SOLICITUD No. SP-12-12359 PCT)
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 8680
Patent: ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ДРОСПИРЕНОН, И НАБОР ДЛЯ ПРЕДУПРЕЖДЕНИЯ ЗАЧАТИЯ (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT)
Estimated Expiration: ⤷ Sign Up
Patent: 1291372
Patent: ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ДРОСПИРЕНОН, И НАБОР ДЛЯ ПРЕДУПРЕЖДЕНИЯ ЗАЧАТИЯ
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 88114
Patent: COMPOSITION PHARMACEUTIQUE CONTENANT DE LA DROSPIRÉNONE ET KIT CONTRACEPTIF (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT)
Estimated Expiration: ⤷ Sign Up
Patent: 32448
Patent: COMPOSITION PHARMACEUTIQUE COMPRENANT DE LA DROSPIRÉNONE ET ENSEMBLE CONTRACEPTIF (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT)
Estimated Expiration: ⤷ Sign Up
Patent: 56186
Patent: COMPOSITION PHARMACEUTIQUE COMPRENANT DE LA DROSPIRÉNONE ET ENSEMBLE CONTRACEPTIF (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT)
Estimated Expiration: ⤷ Sign Up
France
Patent: C1020
Estimated Expiration: ⤷ Sign Up
Patent: C1031
Estimated Expiration: ⤷ Sign Up
Guatemala
Patent: 1200336
Patent: COMPOSICIÒN FARMACÈUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO
Estimated Expiration: ⤷ Sign Up
Patent: 1200336A
Patent: COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO (SOLICITUD DIVISIONAL NO. 1)
Estimated Expiration: ⤷ Sign Up
Patent: 1200336B
Patent: COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO (SOLICITUD DIVISIONAL NO. 2)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 47689
Estimated Expiration: ⤷ Sign Up
Patent: 58176
Estimated Expiration: ⤷ Sign Up
Patent: 000016
Estimated Expiration: ⤷ Sign Up
Patent: 200018
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 10159
Estimated Expiration: ⤷ Sign Up
Patent: 13529665
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 2021523
Estimated Expiration: ⤷ Sign Up
Patent: 2022513
Estimated Expiration: ⤷ Sign Up
Patent: 88114
Estimated Expiration: ⤷ Sign Up
Patent: 32448
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 9952
Patent: COMPOSICION FARMACEUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO. (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT.)
Estimated Expiration: ⤷ Sign Up
Patent: 4971
Patent: COMPOSICION FARMACEUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO. (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT.)
Estimated Expiration: ⤷ Sign Up
Patent: 12014629
Patent: COMPOSICION FARMACEUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO. (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT.)
Estimated Expiration: ⤷ Sign Up
Patent: 19004393
Patent: COMPOSICION FARMACEUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO. (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT.)
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 5176
Patent: Pharmaceutical composition comprising drospirenone and contraceptive kit
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 20015
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 130780
Patent: COMPOSION FARMACEUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO
Estimated Expiration: ⤷ Sign Up
Patent: 161410
Patent: COMPOSICION FARMACEUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 88114
Estimated Expiration: ⤷ Sign Up
Patent: 32448
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 88114
Estimated Expiration: ⤷ Sign Up
Patent: 32448
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 826
Patent: FARMACEUTSKA KOMPOZICIJA KOJA OBUHVATA DROSPIRENON I KONTRACEPTIVNI KOMPLET (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT)
Estimated Expiration: ⤷ Sign Up
Patent: 027
Patent: FARMACEUTSKA KOMPOZICIJA KOJA OBUHVATA DROSPIRENON ZA UPOTREBU KAO KONTRACEPTIV (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE FOR USE AS A CONTRACEPTIVE)
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 88114
Estimated Expiration: ⤷ Sign Up
Patent: 32448
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1209743
Patent: PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2164693
Estimated Expiration: ⤷ Sign Up
Patent: 2210982
Estimated Expiration: ⤷ Sign Up
Patent: 2539030
Estimated Expiration: ⤷ Sign Up
Patent: 130048227
Patent: PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT
Estimated Expiration: ⤷ Sign Up
Patent: 170085604
Patent: 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트 (Pharmaceutical composition comprising drospirenone and contraceptive kit)
Estimated Expiration: ⤷ Sign Up
Patent: 190073598
Patent: 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트 (Pharmaceutical composition comprising drospirenone and contraceptive kit)
Estimated Expiration: ⤷ Sign Up
Patent: 210013663
Patent: 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트 (Pharmaceutical composition comprising drospirenone and contraceptive kit)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 77886
Estimated Expiration: ⤷ Sign Up
Patent: 08657
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering SLYND around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2011273605 | Pharmaceutical composition comprising drospirenone and contraceptive kit | ⤷ Sign Up |
| France | 22C1031 | ⤷ Sign Up | |
| Croatia | P20220332 | ⤷ Sign Up | |
| Portugal | 2588114 | ⤷ Sign Up | |
| Lithuania | 3632448 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SLYND
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0398460 | 04C0022 | France | ⤷ Sign Up | PRODUCT NAME: ESTRADIOL ANHYDRE DROSPIRENONE; REGISTRATION NO/DATE IN FRANCE: NL 28661 DU 20040316; REGISTRATION NO/DATE AT EEC: RVG 27505 DU 20021211 |
| 2588114 | 122021000065 | Germany | ⤷ Sign Up | PRODUCT NAME: DROSPIRENON; NAT. REGISTRATION NO/DATE: 7002248.00.00 20210426; FIRST REGISTRATION: DK 61678 20191016 |
| 2588114 | CA 2020 00023 | Denmark | ⤷ Sign Up | PRODUCT NAME: DROSPIRENON; NAT. REG. NO/DATE: 61678 20191016; FIRST REG. NO/DATE: DK 61678 20191016 |
| 2588114 | C202030026 | Spain | ⤷ Sign Up | PRODUCT NAME: DROSPIRENONA; NATIONAL AUTHORISATION NUMBER: 84603-SE/H/1869/001/DC; DATE OF AUTHORISATION: 20191025; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 61678; DATE OF FIRST AUTHORISATION IN EEA: 20191016 |
| 2588114 | LUC00227 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: DROSPIRENONE; AUTHORISATION NUMBER AND DATE: 31332 20191022 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
